Tsc1iΔEC Tumor model for lymphangiosarcoma mouse
Invented at University Of Cincinnati
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 160865 |
| Antigen/Gene or Protein Targets | Tsc1/Hamartin |
| Disease Keywords | Angiosarcoma, Lymphangiosarcoma |
| Model | Conditional KO |
| Relevance | Angiosarcoma/lymphangiosarcoma is a rare cancer that currently has no effective treatment. The mechanism of angiosarcoma development is largely unknown, and there is no animal model for the disease with molecularly defined pathogenesis. Loss of Tsc1 can cause hyper-activation of mTORC1 signaling in endothelial cells, which results in the development of lymphatic malformation (LM) and progression to vascular tumors that recapitulate salient features of human lymphangiosarcoma (LAS), including local invasion and systemic metastasis. |
| Production Details | Cohorts of Tsc1f/f;Scl-Cre and control littermates mice at 8-10 weeks of age were intraperitoneally injected with tamoxifen for three times (2 mg each time, every other day) to induce activation of Cre recombinase to delete floxed Tsc1 gene in endothelial cells. |
| Breeding Information | Exceptional breeder (8 pups per litter) |
| Conditional | Yes |
| Strain | C57BL/6 |
| Mouse Genetic Background/Cross History | Tsc1f/f mice crossed with End-Scl-Cre-ERT transgenic mice to produce Tsc1f/f;Scl-Cre mice. |
| Zygosity | Homozygous |
| Research Area | Cancer, Drug Discovery & Development |
References: 2 entries
Yang et al. 2020. Br J Cancer. 122(12):1791-1802. PMID: 32336756.
Sun et al. 2015. Cancer Cell. 28(6):758-772. PMID: 26777415.
Add a reference
References: 2 entries
Yang et al. 2020. Br J Cancer. 122(12):1791-1802. PMID: 32336756.
Sun et al. 2015. Cancer Cell. 28(6):758-772. PMID: 26777415.
Add a reference
